BIOA: the cashflow

MyFinsight

For the quarter ending 2025-09-30, BIOA had -$4,757K decrease in cash & cash equivalents over the period. -$16,066K in free cash flow.

Unit: Thousand (K) dollars (except for numbers of shares and EPS)

Cash Flow	2025-09-30	2025-06-30
Net loss	-20,171	-34,491
Stock-based compensation expense	2,791	6,178
Depreciation expense	49	95
Loss on extinguishment of debt	0	0
Non-cash interest expense	16	140
Non-cash lease expense	2	113
(gain) loss from changes in fair value on warrants	42	-48
Accounts receivable	-88	603
Prepaid expenses and other current assets	436	1,045
Other assets	-10	-3
Accounts payable	3,645	-550
Accrued expenses and other current liabilities	-542	-4,224
Deferred revenue	-1,538	-2,900
Deferred grant income	0	-
Net cash used in operating activities	-16,044	-37,332
Purchase of property and equipment	22	585
Purchases of marketable securities	12,887	101,544
Maturities of marketable securities	25,750	8,500
Net cash used in investing activities	12,841	-93,629
Proceeds from series d issuance	0	0
Issuance costs paid on series d issuance	0	0
Proceeds from initial public offering, net of underwriting discounts and commissions	0	-
Issuance costs paid on initial public offering and private placement	0	-
Proceeds from issuance of common shares through private placement, net of placement agent fees	0	-
Term loan principal payments	1,500	3,000
Deferred offering costs paid	44	0
Proceeds from issuance of common shares upon stock option exercises	0	0
Net cash (used in) provided by financing activities	-1,544	-3,000
Effect of changes in exchange rate on cash and cash equivalents	-10	-58
Net (decrease) increase in cash and cash equivalents	-4,757	-134,019
Cash and cash equivalents at beginning of period	354,349	-
Cash and cash equivalents at end of period	215,573	-

Unit: Thousand (K) dollars